Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FSD Pharma Inc C.HUGE

Alternate Symbol(s):  HUGE

Healthcare Cannabis
FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is... see more

Recent & Breaking News (CSE:HUGE)

FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements

Business Wire February 15, 2023

FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse

Business Wire February 14, 2023

FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate

Business Wire February 7, 2023

Recruiting Underway in FSD Pharma's Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

Business Wire January 30, 2023

FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation

Business Wire January 17, 2023

FSD Pharma (CSE:HUGE) announces NCIB

John Ballem  January 13, 2023

FSD Pharma Announces Share Repurchase Program

Business Wire January 13, 2023

FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

Business Wire January 9, 2023

FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023

Business Wire January 6, 2023

FSD Pharma Announces Changes to the Board of Directors

Business Wire November 28, 2022

FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari

Business Wire November 10, 2022

FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Business Wire September 29, 2022

FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available

Business Wire September 12, 2022

FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome

Business Wire September 6, 2022

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium

Business Wire July 13, 2022

FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates

Business Wire June 27, 2022

FSD Pharma Files Investigational New Drug Application ("IND") with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates

Business Wire May 31, 2022

FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs

Business Wire May 24, 2022

FSD Pharma closes $16 million-plus sale of non-core assets

Stockhouse Editorial May 11, 2022

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

Business Wire May 10, 2022